Research Articles - Retinitis Pigmentosa
A Foundation-funded research team has developed a gene therapy that restored vision in mice which had lost half of their photoreceptors to autosomal recessive retinitis pigmentosa (arRP) caused by mutations in the gene PDE6α. Results of the study, led by Stephen Tsang, M.D., Ph.D., of Columbia University, were published in the journal Human
- The three-year, 90-participant clinical study will be conducted at three sites — the University of Massachusetts Medical School, the University of Utah, and the Retina Foundation of the Southwest — under the auspices of the National Eye Evaluation Research Network. The Foundation Fighting Blindness established the network to launch clinical trials of promising treatments and cures for retinal degenerative diseases. Valproic acid is the first treatment to be evaluated in the network.
Valproic acid appears to work by masking certain protein defects that can cause
- While Second Sight Medical Products is actively moving out its Argus II retinal prosthesis systems to blind patients in the United States and Europe, the developer of the first commercially available bionic retina also has its eye on the future. The company is working on a number of upgrades and enhancements to restore vision in more patients and improve the visual experience for existing users.
In a presentation at the Foundation’s
- By genetically reprogramming rods to become like cones, researchers from the Washington University School of Medicine in St. Louis may have found an innovative way to treat vision-robbing retinal diseases like retinitis pigmentosa (RP). While their research is at an early stage in mice, it has revealed valuable clues about how to potentially save vision in people. Results of the study were published in a recent online edition of Proceedings of the National Academy of Sciences.
- Thanks to success in preclinical studies funded in part by the Foundation Fighting Blindness, the Irish biopharmaceutical company Genable Technologies has received a €5 million (equivalent to about $6.8 million) venture capital investment to advance its gene therapy for autosomal dominant retinitis pigmentosa (adRP) into a clinical trial.
A Foundation-funded investigative team led by Ruifang Sui, M.D., Ph.D., of Peking Union Medical College Hospital, has completed the first comprehensive genetic screening of a group of Chinese people with autosomal recessive retinitis pigmentosa (arRP). Results of the
The Argus II® Retinal Prosthesis System, which restores some useful vision to people blind from advanced retinitis pigmentosa, will be offered later this year at 12 clinical centers throughout the United States.
The Argus II retinal prosthesis, a device that can restore some vision to people who are blind from advanced retinitis pigmentosa (RP), has received U.S. market approval from theFood and Drug Administration (FDA). Developed by Second Sight Medical Products, the device will be available later this year in approximately 10 clinical centers across the country. In 2011, the Argus II received marketing approval in Europe. Also known as a “bionic retina,” it is currently the world’s only retinal
The Alpha IMS, a subretinal implant developed by Retina Implant AG of Reutlingen, Germany, has been granted European marketing approval. The device received a CE Mark, a regulatory designation for meeting European safety and reliability standards. Also known as an artificial or bionic retina, the Alpha IMS has
An artificial retina developed by Retina Implant AG of Reutlingen, Germany, has restored meaningful vision to most of the nine blind people — eight with retinitis pigmentosa, one with cone-rod dystrophy — enrolled in a clinical trial. Five of the participants recognized objects such as door knobs, telephones and facial features. One person was able to read store and restaurant signs, and another was able to observe the movements of a wild goose.
Interim results of the clinical trial were published online in